A diagnosis ofchronic pancreatitis is currently based on clinical features together with the findings of plain radiographs of the abdomen, abdominal ultrasound, computerised axial tomography, pancreatic secretory studies or endoscopic retrograde cholangiopancreatography (ERCP). Apart from calcification on plain radiographs of the abdomen, the only established diagnostic tests are pancreatic secretory studies or ERCP. The latter investigations, however, are invasive, time consuming, and uncomfortable for the patient.1 We have developed a means of assessing pancreatic function by the measurement of pancreatic polypeptide levels in serum after the intravenous injection of secretin. 2 strictures, areas of dilatation, and ductal filling defects.
Of the nine patients with moderate chronic pancreatitis, all had a single stricture of the main pancreatic duct in the head or body of the pancreas with dilatation of proximal ducts. All 13 patients with minimal chronic pancreatitis had dilatation, irregularity, and obstruction of side-branches only.
TECHNIQUES
After an overnight fast an indwelling catheter was inserted into the antecubital vein and kept patent with repeated saline flushing. A rapid intravenous injection of 2 units/kg of Boots secretin was given and blood was taken 30 and 15 minutes before and at times 0, 5, 10, 15, 20, 30, 45, and 60 minutes after injection. An aliquot of blood taken before secretin injection was used for glucose estimation by the glucose oxidase method to confirm euglycaemia in all patients before secretin injection. Sera were coded, stored at -200C, and assayed 'blind' by a sensitive and specific radioimmunoassay (RIA) which has been previously described. When the pancreatic polypeptide response for each individual was calculated as a peak:basal pancreatic polypeptide ratio, similar results were seen (Fig. 2) . The ratio was significantly lower in patients with advanced (P<0-005) or moderate (P<0.01) chronic pancreatitis than in control subjects. Previous studies in 50 patients with documented advanced chronic pancreatitis and 33 controls showed that 90% of chronic pancreatitis patients had a peak:basal pancreatic polypeptide ratio of less than 5, whereas 91% ofcontrols had a peak:basal ratio of greater than 5.2 3 Pancreatic polypeptide levels rise with age9 and for this reason absolute levels, whether basal or stimulated, are of little value in the assessment of chronic pancreatitis. However, the peak:basal pancreatic polypeptide ratio appears a better index of pancreatic function and the lower limit of normal has been defined as 5. In the present study an abnormal pancreatic polypeptide response was present in nine of 10 patients categorised as having advanced chronic pancreatitis and in eight of nine patients categorised as having moderate chronic pancreatitis. All patients with minimal chronic pancreatitis and all controls had a normal peak:basal pancreatic polypeptide ratio.
Discussion
The results of this study confirm previous observations2 3 of impaired secretin-stimulated pancreatic polypeptide release in chronic pancreatitis. These observations suggest a loss of functioning pancreatic polypeptide cells which is consistent with a generalised destructive and fibrosing process and imply that the magnitude of the pancreatic polypeptide response may be related to the severity of the disease. Previous studies in chronic pancreatitis have been performed using a protein-rich meal10 " or insulininduced hypoglycaemia`2 as the stimulus of pancreatic polypeptide release. The pancreatic polypeptide response to food was a poor means of differentiating patients with chronic pancreatitis from control subjects, while additional studies are necessary to define the value of the response induced by hypoglycaemia. Previous studies by others have shown that pure (GIH) secretin does not release pancreatic polypeptide when given by slow infusion;`3 14 when given as a bolus injection, however, both forms of secretin have an equivalent pancreatic polypeptide stimulatory effect.'5 The lack of effect of secretin infusion may be due to plastic absorbtion, of secretin by the infusion apparatus.`6 The response to either form of secretin was shown to be reproducible, reliable, and dependent on extravagal mediation.
A previous study2 3 showed a peak:basal pancreatic polypeptide ratio of less than 5 in 90% of patients with advanced chronic pancreatitis and the present study was designed to evaluate the sensitivity of this test in milder forms of the disease. The degree of abnormality of the retrograde pancreatogram was chosen as the criterion for categorisation of patients and was validated, in part, by the presence of other features such as pancreatic calcification, malabsorption, and diabetes mellitus as shown in the Table. The pancreatic polypeptide response was abnormal in 17 of 19 patients (90%) with moderate or advanced chronic pancreatitis but was normal in all patients with minimal disease. Two patients with established chronic pancreatitis had a normal pancreatic polypeptide response, presumably indicating relative sparing of pancreatic polypeptide cells. Both patients had chronic pancreatitis related to alcohol abuse and one had pancreatic calcification on plain radiographs of the abdomen. The data did not support the possibility of greater destruction of polypeptide cells in alcoholic pancreatitis than in idiopathic or gallstone pancreatitis in those patients with moderate or advanced disease (although only three non-alcoholic patients were studied). The reasons for a false negative rate of 10% remains unclear but similar findings have been observed with standard pancreatic secretory studies including Lundh tests. '7 18 The advantage of this test over standard pancreatic function tests is that it is quickly done and not uncomfortable for the patient. All patients responded with a peak pancreatic polypeptide level usually at five minutes -and, at the latest, at 15 minutes -after injection of secretin. Thus this test need take no more than half an hour and involves only the injection of secretin and the drawing of blood samples by a trained nursing sister. It does not demand highly trained staff, radiology facilities and screening time, is not invasive, and is well accepted by patients. Radioimmunoassay facilities are available in most major centres -the pancreatic polypeptide radioimmunoassay being simple and easily performed.
The present study, showing an abnormal pancreatic polypeptide response in 90% of patients with moderate or advanced chronic pancreatitis at ERCP, corroborates our previous studies2 3 in which an abnormal response was found in 90% ofpatients with an abnormal standard secretory test. Furthermore, preliminary studies suggest that an abnormal panereatic polypeptide response is specific for chronic pancreatitis; the response being normal in patients who have undergone vagotomy 15 (and unpublished observation) and in most patients with pancreatic cancer (unpublished observation). Although other diseases will need to be looked at, it seems likely that the pancreatic polypeptide response to secretin may be an attractive alternative investigation for evaluation ofthe severity ofpancreatic damage.
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